PD-L1 CPS in Gastroesophageal Cancer: Care vs. Trials

Bioengineer.org·Apr 18

This story is reported by Bioengineer.org. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Nature·Apr 18

2

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

The Lancet·Jun 1

3

Triplet Therapy Clears Early Hurdle in Gastric Cancer

Oncology News Central·Feb 2

4

Cadonilimab Plus Chemo Retains Clinically Meaningful Survival Advantage in Frontline Gastric/GEJ Adenocarcinoma

OncLive·Oct 23

5

ASCO GI 2026 | Henlius Accelerates Global Phase 3 Head-to-Head Development of HLX22 as First-Line Treatment for HER2-Positive Gastric Cancer-Media

复宏汉霖·Jan 9

6

PFS as a Surrogate for OS in First-Line Immunotherapy: Results from 18 Trials Meta-Analysis in GEA and ESCC

Oncodaily·Dec 11

7

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Nature·Mar 16

8

How to Choose Between New Gastric Cancer Treatments Without Head-to-Head Comparisons

Oncology News Central·Dec 8